NCT01959490View on ClinicalTrials.gov

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 24, 2013

Primary Completion Date

November 11, 2016

Study Completion Date

March 29, 2017

Conditions
Stage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
Interventions
BIOLOGICAL

trastuzumab

Given IV

BIOLOGICAL

Pertuzumab

Given IV

DRUG

docetaxel

Given IV

DRUG

carboplatin

Given IV

DRUG

doxorubicin

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

paclitaxel

Given IV

DRUG

Bevacizumab

Trial Locations (1)

44106-5065

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT01959490 - Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer | Biotech Hunter | Biotech Hunter